Nuvectis Pharma, Inc.
NVCTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Nuvectis Pharma, Inc. (NVCT) is listed under Biotechnology. The company carries a $617.6M market cap, placing it firmly in the small-cap category. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Market Cap
$617.6M
Beta
-0.25
P/E (TTM)
—
P/E (Fwd)
-20.41
EPS (TTM)
$-1.40
EPS (Fwd)
$-0.96
ROE
-154.4%
ROA
-63.6%
Cash
$25.1M
Total Debt
$0
Free CF
-$9.2M
52W Change
139.8%
Annual Financials
Cash vs Debt
Nuvectis Pharma, Inc. reports $25.1M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$9.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -154.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -0.25 suggests NVCT is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Nuvectis Pharma, Inc. and its sector.